Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways. This evidence concerns the gene TGFB1 and thyroid gland undifferentiated (anaplastic) carcinoma.